Cell saver efficacy for routine coronary artery bypass surgery

A retrospective study was conducted to determine the effect of intraoperative Haemonetics Cell Saver® (HCS) usage on postoperative homologous blood product requirements in CABG patients. From 1 January to 31 December 1993, 516 patients without renal disease or postoperative surgical or gastrointesti...

Full description

Saved in:
Bibliographic Details
Published in:Perfusion 1996-01, Vol.11 (1), p.71-77
Main Authors: Sakert, Tamara, Gil, William, Rosenberg, Ian, Carpellotti, Deborah, Boss, Kathy, Williams, Tim, Ferneding, Joseph, Christlieb, Ignacio
Format: Article
Language:English
Subjects:
Aged
Blood Transfusion, Autologous
Coronary Artery Bypass
Cost-Benefit Analysis
Female
Health Care Costs
Hemoglobins - analysis
Humans
Male
Middle Aged
Postoperative Hemorrhage - etiology
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A retrospective study was conducted to determine the effect of intraoperative Haemonetics Cell Saver® (HCS) usage on postoperative homologous blood product requirements in CABG patients. From 1 January to 31 December 1993, 516 patients without renal disease or postoperative surgical or gastrointestinal haemorrhage had elective, first-time CABG surgery. The HCS was utilized in 435 of these patients (Group CS) and in 81 patients the HCS was excluded (Group NCS). Preoperative patient variables were similar in the group. We evaluated the HCS effect on blood product transfusion by comparing x units of red blood cells (RBC), fresh frozen plasma (FFP) and platelets (PLTS) transfused per patient between groups CS and NCS. There were no differences in the x units of RBC (1.9 ± 2.7 CS vs 1.8 ± 1.5 NCS) or in the RBC transfusion rate (48% CS vs 50% NCS). There were also no significant differences between the groups in x units of FFP (0.9 ± 0.8 CS vs 0.4 ± 0.9 NCS) or PLTS (0.7 ± 3.1 CS vs 0.4 ± 2.5 NCS), or in the percentage of patients receiving these products (12% CS vs 8% NCS). These data provide no evidence that the use of the HCS decreases the amount of homologous blood bank products required postoperatively in patients having routine first-time CABG surgery. The current era of aggressive blood conservation may have limited the role of the HCS in routine CABG surgery.
ISSN:0267-6591
1477-111X
DOI:10.1177/026765919601100110